Login / Signup

Benralizumab Reduces Respiratory Exacerbations and Oral Glucocorticosteroid Dose in Patients with Severe Asthma and Eosinophilic Granulomatosis with Polyangiitis.

Carlo MümmlerPontus MertschMichaela BarnikelFrank HaubnerUlf SchönermarckUlrich GrabmaierHendrik Schulze-KoopsJuergen BehrNikolaus KneidingerKatrin Milger
Published in: Journal of asthma and allergy (2024)
In this real-life cohort of patients with severe asthma and EGPA, benralizumab initiation during remission maintenance reduced respiratory exacerbations and daily OCS dose. Benralizumab initiation during remission induction was associated with a high rate of clinical EGPA remission.
Keyphrases
  • chronic obstructive pulmonary disease
  • disease activity
  • cystic fibrosis
  • ulcerative colitis
  • rheumatoid arthritis
  • systemic lupus erythematosus
  • chronic rhinosinusitis